In vitro, the DSF@CuO Gel targets LenR HCC cells by activating the p38/JNK MAPK pathway and inhibiting NF-κB and NOTCH pathways, causing significant mitochondrial and cellular damage. The gene discussed is MAPK8; the disease is hepatocellular carcinoma.